Navigation Links
New Data Analyses from Lorcaserin Phase 3 Clinical Trials to be Presented at Obesity 2011
Date:9/26/2011

in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism. Arena has patents that cover lorcaserin in the United States and other jurisdictions that in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

Arena submitted a New Drug Application (NDA) for lorcaserin to the FDA in December 2009, and the FDA issued a Complete Response Letter (CRL) in October 2010. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States subject to FDA approval of the lorcaserin NDA.

Lorcaserin Phase 3 Clinical Trial Program OverviewThe lorcaserin Phase 3 clinical trial program consists of three double-blind, randomized, placebo-controlled trials – BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) and BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) – that together enrolled approximately 7,800 patients. BLOOM and BLOSSOM evaluated lorcaserin versus placebo in obese patients or overweight patients with at least one weight-related co-morbid condition. BLOOM evaluated 3,182 patients over a two-year treatment period, and BLOSSOM evaluated 4,008 patients over a one-year treatment period. BLOOM-DM evaluated 604 obese and overweight patients with type 2 diabetes over a one-year treatment period. The trials included a standardized program of moderate diet and exercise guidance.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major th
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... NxStage Medical, Inc. (NASDAQ: NXTM ... announced today that the U.S. Food and Drug ... perform hemodialysis overnight while the patient is at ... System One is the first and only hemodialysis ... Home nocturnal hemodialysis is an ...
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... the following open letter to shareholders from President ... Sc. Dear RXi Shareholders, ... inaccurate statements posted on certain social media sites ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... former senior vice president and corporate controller, has been ... effective immediately, replacing Peggy Mulligan, former chief financial officer, ... other interests.  The Company has initiated a search to ...
... (Nasdaq: STXS ) announced today that the Company ... which includes a $30 million revolving facility that matures on ... matures on December 31, 2013.  The new facility was led ... that was scheduled to mature in March 2011. ...
Cached Medicine Technology:Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO 2Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO 3Stereotaxis Completes $40 Million Credit Facility 2Stereotaxis Completes $40 Million Credit Facility 3
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast and ... landscape, unmet needs, current pipeline and commercial opportunities in ... which is typically used for treating colorectal cancer. It ... gastric cancer and pancreatic cancer. TS-1 is composed of ... approved in 1999 in Japan for the treatment of ...
(Date:12/25/2014)... The short film “Color of Honor” by young director/producer ... true 9/11 hero, Welles Remy Crowther. It has been chosen ... of Nuremberg International Short Film Festival and the 8th International ... and director Luciana Lagana plays the mother of the ... Gregory Graham - Graham plays a heroic policeman ...
(Date:12/25/2014)... 2014 Recently, LunaDress.co.uk has updated its blog to ... accessories. Now, all of the models at LunaDress.co.uk come with big ... lifts the wedding veil can turn out to be a most ... wedding veil can always bring surprise to a wedding. On the ... to choose veils for a big day . , Going ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... a "fountain of youth" drug that can delay the effects ... new study suggests. Seniors received a significant boost to ... genetic signaling pathway linked to aging and immune function, researchers ... experimental medication, a version of the drug rapamycin, improved the ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... effect , MONDAY, Oct. 5 (HealthDay News) -- Although ... this isn,t reason enough for most people to stop eating ... blood pressure due to methylmercury will never outweigh the benefits ... in the department of social and preventive medicine at Laval ...
... desired antibodies in some, but effects were fleeting, scientists say ... help cocaine addicts beat their habit is showing some effect ... more than one-third of participants in a new study developed ... this group, cocaine use did go down. But the effects ...
... New Delhi, Singapore and Washington DC (October 5, 2009) SAGE ... by Dr. Prem Reddy, founder and previous Editor-in-Chief of the ... field of cancer research is entering a new and exciting ... modern genetics are beginning to provide new clues into how ...
... Fewer secondary schools in the United States are selling ... according to a survey from the Centers for Disease Control ... in states that have adopted strong school nutrition standards and ... , The report, "Availability of Less Nutritious Snack Foods ...
... Mass., Oct. 5 Hologic, Inc. (Hologic or the ... and supplier of premium diagnostics, medical imaging systems and ... women, today announced plans to release its fourth quarter ... 2009 after market close. In conjunction with the release, ...
... Fred Hutchinson Cancer Research Center have been awarded 60 ... Recovery & Reinvestment Act of 2009. The totals reflect ... the National Institutes of Health. , The individual projects ... benefit every level of researcher at the Hutchinson Center, ...
Cached Medicine News:Health News:Mercury in Fish Linked to High Blood Pressure 2Health News:Mercury in Fish Linked to High Blood Pressure 3Health News:Cocaine Addiction Vaccine Shows Some Success 2Health News:Cocaine Addiction Vaccine Shows Some Success 3Health News:SAGE launches Genes & Cancer 2Health News:Fewer U.S. Schools Selling Less Nutritious Food and Beverages 2Health News:Hologic to Release Fourth Quarter and Fiscal 2009 Operating Results on Monday, November 9, 2009 2Health News:Federal Stimulus Funding Channels More Than $40 Million to Fred Hutchinson Cancer Research Center 2Health News:Federal Stimulus Funding Channels More Than $40 Million to Fred Hutchinson Cancer Research Center 3Health News:Federal Stimulus Funding Channels More Than $40 Million to Fred Hutchinson Cancer Research Center 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: